GlobeNewswire

Cisco Container Platform Enables Production-Grade Multicloud Environments

Dela

Kubernetes-based Turnkey Software Platform Provides Consistent Deployment and Management for Containerized Applications Across Private and Public Cloud Environments

 

BARCELONA, Spain, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Cisco today announced the Cisco® Container Platform, a turnkey, open, and production-grade software container platform to address customers' growing need to have applications seamlessly run the same way on premises and in public clouds. The Cisco Container Platform simplifies and accelerates how application development and information technology (IT) operations teams configure, deploy, and manage container clusters based on 100 percent upstream Kubernetes. The new solution expands Cisco's growing portfolio of other leading container platform offerings, providing more choice for customers.

The Cisco Container Platform enables an open, multicloud environment with consistent application deployment and management on multiple deployment platforms, including Cisco HyperFlex(TM), virtual machines (VMs), and bare metal, both on premises and in the cloud. With this range of deployment options, the Cisco Container Platform helps protect customers' existing infrastructure investments and enables IT to run applications where they are most effective, seamlessly transitioning between private and public clouds.

Open, flexible and extensible
The Cisco Container Platform provides an extensible platform for container management based on industry standards with an open architecture and open-source components. The solution addresses the end-to-end management of container clusters including setup, orchestration, authentication, monitoring, networking, load balancing, and optimization. The Cisco Container Platform is also extensible to other open deployment environments and to networking (Contiv), security, analytics, and management tools.

As a single solution that automates repetitive tasks, the Cisco Container Platform can help increase operational efficiencies and drive faster time to value by eliminating the need for IT teams to source, configure, and support multiple disparate solutions. This simplifies deployment and management of production-grade container environments. Cisco will also offer new services to help customers modernize traditional applications, and optimize containers for scale and performance, and provide enterprise-class support for the Cisco Container Platform.

Optimized for Cisco infrastructure
The Cisco Container Platform, working with other Cisco technologies, enables customers to have the easiest and most seamless deployment experience, while extending the value of new and existing Cisco investments. The Cisco Container Platform will initially be released on, and be optimized for Cisco HyperFlex 3.0 and can be licensed separately or as an integrated solution.  The Cisco Container Platform also includes Contiv for container networking which can be further integrated with Cisco Application Centric Infrastructure (Cisco ACI(TM)), enabling customers to deploy containers and build ACI network policy definitions through Kubernetes.

Optimized in collaboration with Google Cloud
Cisco and Google Cloud have worked closely to extend and optimize the Kubernetes platform for on-premises production environments, providing customers with a consistent environment and the confidence to move workloads between private and public clouds. The Cisco Container Platform is a key element of the open, hybrid cloud offering from Cisco and Google, announced in October and planned for availability in 2018. Customers will be able to run robust, enterprise-ready containers on any infrastructure through the combination of the Cisco Container Platform and the Google Kubernetes Engine (GKE), part of the Google Cloud Platform (GCP).

Packaging and availability
The Cisco Container Platform will be available as:

  • Software optimized with Cisco HyperFlex 3.0; available in April 2018.
  • Software supported on VM infrastructure, bare metal, public cloud; available in summer 2018.

Pricing will be subscription-based on number of cluster nodes deployed, with volume-based discounts.

Eyal Manor, Vice President, Engineering, Google
"As the adoption of Kubernetes has exploded, container orchestration and management have become of paramount importance to customers because they enable application portability and consistency across on premises and cloud-based environments. Cisco Container Platform is optimized in collaboration with Google Cloud to deliver a next-generation open hybrid cloud architecture, and represents an important milestone for our integrated Google and Cisco hybrid cloud solution coming later this year."

Dr. Thomas Scherer, Chief Architect,  Telindus SA
"As a cloud provider and integrator, we are offering container platforms to our customers, and understand the importance to have such environments available to help them increase business agility. As a Cisco customer and partner, we are excited that Cisco is delivering the Cisco Container Platform to provide a truly consistent hybrid container architecture stretching public and private clouds. This will enable our customers to unify processes and tooling. Moreover, the combined strengths of Cisco's networking expertise and Google's cloud expertise will certainly help to further improve the level of segregation across microservices to better isolate shared hosting of business critical services."

Stephen Elliott, Program Vice President, IDC
"In the multicloud era, enterprise IT executives are looking to modernize traditional applications, and manage containerized applications in a consistent way across public and private clouds. Container deployment, management and monitoring are key requirements to drive speed and quality improvements for the business, and enable scale for IT operations teams. In addition, operations teams also require multiplatform support, including Kubernetes, while helping customers address the end-to-end lifecycle management of container clusters."

Kip Compton, VP, Cloud Platform and Solutions Group, Cisco
"Cisco is focused on enabling customers' multicloud ambitions. Cisco Container Platform helps customers realize the potential of Kubernetes and containers, simplifying the deployment and management of Kubernetes clusters in a multicloud environment with enterprise-class security and compliance."

Ed Horley,  Vice President of Engineering, Groupware Technology  (Cisco Gold Channel Partner) 
"Application containers have emerged as a top-of-mind technology for our customers as they refine their DevOps strategies. We also see a big opportunity to help our Cisco installed base as well as other customers realize optimal value with a multicloud strategy through container integration services. By advising, consulting and migrating our customers to Kubernetes and containers, they are now one step closer to freeing themselves from cloud provider lock-in. With the Cisco Container Platform, customers can now have confidence in this technology with the backing of Cisco."

Links to additional information:

Visit the Cisco Container Platform website 
Cisco Cloud Blog about the Cisco Container Platform 
Cisco Executive Blog: Cisco Container Platform & Google Cloud Solution by Kip Compton, VP, Cloud Platform and Solutions Group 
Cisco Container Platform at a Glance 
TechWiseTV episode featuring Cisco Container Platform 
IDC Technology Spotlight: Container Management Platforms 
News release: Cisco and Google Partner on New Hybrid Cloud Solution 
Cisco Container Services

About Cisco 
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at thenetwork.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds

Press Contact:
Charles Sommerhauser
(925) 371-6341
csommerh@cisco.com

Industry Analyst Contact:
Mona Faulkner
(832) 687-6995
mfaulkne@cisco.com

Investor Relations Contact:
Marilyn Mora
(408) 527-7452
marilmor@cisco.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum